Amedisys Incorporated (NASDAQ:AMED)’s Trend Up, Especially After Decreased Shorts

December 7, 2017 - By Louis Casey

 Amedisys Incorporated (NASDAQ:AMED)’s Trend Up, Especially After Decreased Shorts

Investors sentiment increased to 1.75 in 2017 Q2. Its up 0.69, from 1.06 in 2017Q1. It is positive, as 9 investors sold Amedisys, Inc. shares while 42 reduced holdings. 32 funds opened positions while 57 raised stakes. 30.18 million shares or 2.20% less from 30.86 million shares in 2017Q1 were reported.
Rafferty Asset Mngmt Lc owns 13,748 shares for 0.02% of their portfolio. Ahl Partners Limited Liability Partnership, United Kingdom-based fund reported 47,994 shares. Tci Wealth Advisors stated it has 0% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). Tower Research Cap Limited Company (Trc), New York-based fund reported 100 shares. Riggs Asset Managment Co Incorporated owns 450 shares. Alaska-based State Of Alaska Department Of Revenue has invested 0.02% in Amedisys, Inc. (NASDAQ:AMED). Acadian Asset has invested 0.02% in Amedisys, Inc. (NASDAQ:AMED). Royal Financial Bank Of Canada owns 6,237 shares or 0% of their US portfolio. Loomis Sayles & Limited Partnership has 118 shares. Denver Ltd Llc holds 8,385 shares or 0.02% of its portfolio. 819,433 are held by Gilder Gagnon Howe Ltd Llc. Fmr Ltd Liability Company invested in 1.72 million shares. Timessquare Cap Ltd Llc owns 0.3% invested in Amedisys, Inc. (NASDAQ:AMED) for 731,670 shares. Envestnet Asset Management holds 46 shares. Retail Bank Of Ny Mellon Corp holds 0.01% or 764,328 shares in its portfolio.

The stock of Amedisys Incorporated (NASDAQ:AMED) registered a decrease of 3.44% in short interest. AMED’s total short interest was 2.89M shares in December as published by FINRA. Its down 3.44% from 2.99 million shares, reported previously. With 319,100 shares average volume, it will take short sellers 9 days to cover their AMED’s short positions. The short interest to Amedisys Incorporated’s float is 8.79%.

The stock increased 0.59% or $0.31 during the last trading session, reaching $52.96. About 573,865 shares traded or 40.11% up from the average. Amedisys, Inc. (NASDAQ:AMED) has risen 15.02% since December 7, 2016 and is uptrending. It has underperformed by 1.68% the S&P500.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $1.80 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 42 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Amedisys, Inc. (NASDAQ:AMED) Ratings Coverage

Among 14 analysts covering Amedisys Inc. (NASDAQ:AMED), 6 have Buy rating, 0 Sell and 8 Hold. Therefore 43% are positive. Amedisys Inc. had 36 analyst reports since September 1, 2015 according to SRatingsIntel. The company was initiated on Friday, January 27 by Benchmark. The company was upgraded on Monday, January 11 by Raymond James. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Outperform” rating by Wells Fargo on Tuesday, September 1. As per Thursday, November 9, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained it with “Hold” rating and $5600 target in Monday, June 5 report. The rating was initiated by Stephens with “Equal-Weight” on Friday, June 17. The rating was upgraded by Mizuho on Tuesday, January 19 to “Buy”. Jefferies maintained the stock with “Buy” rating in Wednesday, July 19 report. On Monday, February 8 the stock rating was upgraded by Oppenheimer to “Outperform”. The firm has “Hold” rating by RBC Capital Markets given on Monday, August 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.